CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

7 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion

80%

bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss

70%

bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition

60%

neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture

50%

bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback

40%

Filing History

10-QMay 7, 2026

The Q1 2026 filing presents a company in the midst of a high-stakes transformation. On one hand, the operational metrics suggest a successful lean-out, with significant margin gains and a strategic pivot away from underperforming assets. On the other hand, the financial results are marred by heavy one-time charges and a worrying contraction in cash flow, indicating that the 'turnaround' is currently being funded by debt and asset sales rather than organic growth. Investors are left to weigh the validity of the 60% operating income jump against the reality of a net loss and rising leverage. The successful vertical integration of the NHP supply chain is a long-term strategic win, but the immediate pressure of a flat backlog and legal contingencies creates a volatile environment. The overall impact of the filing is a shift from a growth-at-all-costs model to a margin-preservation model, though the transition is proving costly and debt-intensive.